TrialDoor helps pancreatic cancer and colorectal cancer patients and their physicians evaluate potential clinical trials the way an oncologist would, examining each trial in detail with a focus on effectively matching each patient to the most appropriate trial. Using two separate engines (one for pancreatic and one for colorectal) every U.S. trial in the NIH clinicaltrials.gov database appropriate for either pancreatic or colorectal cancer are separately scored daily across 15 clinical dimensions using TrialDoor’s proprietary, diagnosis-specific AI assisted rubric refined over thousands of human-reviewed iterations.

After a brief secure patient input form is completed, the application instantly scores each trial for that specific patient, filters out poor fits and displays the best fits first, reducing the number of trials patients, families, and physicians need to review. A unique and powerful interactive dashboard offers the user to further customize the results, and the final trial set can be easily exported as a pdf report, or as a csv file for importing into a spreadsheet.

The platform is fully secure, encrypted end-to-end, and collects no personal patient identifiers or contact information. AI is used to evaluate trials for suitability for generic patient types, but never touches patient data. TrialDoor is free to use and independent from any healthcare network or pharmaceutical company - it is born from a family caregiver’s determination to help others find better options.